ORX — Orexo AB Share News
0.000.00%
Last trade - 00:00- SEK850.39m
- SEK471.19m
- SEK26.00m
Brief: Orexo Announces Positive Topline Results From Clinical Study
Brief: Orexo To Resolve Patent Litigation With Sun In US
Brief: Orexo And Gaia Terminate Partnership For Deprexis
Brief: Orexo AB - Study Is Expected To Cost Sek 11 Million
Brief: Orexo Q3 EBIT SEK -21.7 Million
Brief: Orexo Maintains Guidance For 2024
Brief: Orexo Q2 EBIT SEK -15.8 Million
US FDA declines to approve Orexo's opioid overdose drug (updated)
US FDA declines to approve Orexo's opioid overdose drug
Brief: Orexo Says Co Received Complete Response Letter FDA Regarding New Drug Application (NDA) For Ox124
Brief: Orexo Sees 2024 Buprenorphine/Naloxone Market To Grow 2-5%
Brief: Orexo Q1 EBIT SEK -4.7 Million
Brief: Orexo AB Says James Noble Was Elected As Chairman Of Board
Brief: Orexo Extends Patent Protection In US
Brief: Orexo Issues Senior Secured Callable Floating Rate Social Bonds Of SEK 500 M
Brief: Orexo Plans Social Bonds Issuance, Tender Offer For Existing Bonds
Brief: Orexo, SOBI Agree To Advance Feasibility Study With Amorphox
Brief: Orexo Sees Positive EBITDA In 2024
Brief: Orexo Q4 EBIT SEK -8.6 Million